Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy

Scandinavian Journal of Urology and Nephrology

Volumn 43, Issue 3, 2009, Pages 206-211

  Kuo, Hann Chorng ^a,b   Liu, Hsin Tzu ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Botulinum toxin; BPH; Lower urinary tract symptoms; Medical treatment

Indexed keywords

ALFUZOSIN; ANTIANDROGEN; BOTULINUM TOXIN A; CIPROFLOXACIN; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; TAMSULOSIN; TERAZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AZASTEROID; CHOLESTENONE 5ALPHA REDUCTASE; ENZYME INHIBITOR;

ADD ON THERAPY; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FLOW RATE; HEMATURIA; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATITIS; QUALITY OF LIFE INDEX; TREATMENT RESPONSE; URINE RETENTION; UROLOGIC SURGERY; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; MIDDLE AGED; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; AZASTEROIDS; BOTULINUM TOXIN TYPE A; CHOLESTENONE 5 ALPHA-REDUCTASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; TREATMENT FAILURE;

EID: 67649133019     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590902811537     Document Type: Article

References (25)

1. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. for the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Groups. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533-9.
2. Marberger MJ. for the PRO-WESS Study Group. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled multicenter study. Urology 1998;51:677-86.
3. AUA Practice Guideline Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170:530-47.
4. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, fnateride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
5. Ventura S, Pennefather J, Mitchelson F. Cholinergic innervation and function in the prostate gland. Pharmacol Ther 2002;94:93-112.
6. Higgins JR, Gosling JA. Studies of the structure and intrinsic innervation of the normal human prostate. Prostate 1989; (Suppl 2):5-16.
7. Gkonos PJ, Krongrad A, Roos BA. Neuroendocrine peptides in the prostate. Urol Res 1995;23:81-7.
8. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the treatment of voiding dysfunction. J Urol 2004; 171:2128-37.
9. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 2004;172:1529-32.
10. Smith C P, Franks ME, McNeil BK, Ghosh R, de Groat WC, Chancellor MB, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003;169:1896-900.
11. Kuo HC. Prostate botulinum A toxin injection - an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005;65:670-4.
12. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA. BOTOX-induced prostatic involution. Prostate 1998;37: 44-50.
13. Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 2006;98:1033-7.
14. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003;62: 259-65.
15. Chuang YC, Huang CC, Kang HY, Chiang PH, Demiguel F, Yoshimura N, et al. Novel action of botulinum toxin on the stroma and epithelial components of the prostate gland. J Urol 2006;175:1158-63.
16. Chuang YC, Tu CH, Huang CC, Kin HJ, Chiang PH, Yoshimura N, et al. Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol 2006; 18(6):12-7.
17. Lin AT, Yang AH, Chen KK. Effects of botulinum toxin A on the contractile function of dog prostate. Eur Urol 2007; 52:582-9.
18. Costa P, Robert M, Sarrazin B, Mottet N, Navratil H. Quantitative topographic distribution of epithelial and mesenchymal components in benign prostatic hyperplasia. Eur Urol 1993;24:120-3.
19. Matsuda T, Fujime M, Suda K. Relationship between the prostatic tissue components and natural history of benign prostatic hyperplasia. Anal Quant Cytol Histol 2006;28: 121-4.
20. Lepor H. The pathophysiology of lower urinary tract symptoms in the ageing male population. Br J Urol 1998; 81(Suppl 1):29-33.
21. Kuo HC. Videourodynamic analysis of pathophysiology of men with both storage and voiding lower urinary tract symptoms. Urology 2007;70:272-6.
22. Chen JL, Kuo HC. Implications of prostatic volume measurements on the degree of bladder outlet obstruction in men with benign prostatic hyperplasia and lower urinary tract symptoms. J Taiwan Urol Assoc 2006;17:41-7.
23. Kuo HC. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol 2003; 170:1908-12.
24. van Melick HH, van Venrooij GE, Eckhardt MD, Boon TA. A randomized controlled trial comparing transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia: analysis of subjective changes, morbidity and mortality. J Urol 2003;169:1411-6.
25. Goya N, Ishikawa N, Ito F, Kobayashi C, Tomizawa Y, Toma H. Transurethral ethanol injection therapy for prostatic hyperplasia: 3-year results. J Urol 2004;172:1017-20.